维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="Martin Markowitz"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immunoglobulin显示文摘	Markowitz JS Martin P Conrad JJ	1998	Hepatology1998，28，2：	1
2	The major genetic determinants of HIV-1control affect HLA class I peptide presentation显示文摘	International HIV Controllers Study Pereyra F Jia X McLaren P J Telenti A de Bakker P I Walker B D Ripke S Brumme C J Pulit S L Carrington M Kadie C M Carlson J M Heckerman D Graham R R Plenge R M Deeks S G Gianniny L Crawford G Sullivan J Gonzalez E Davies L Camargo A Moore JM Beattie N Gupta S Crenshaw A Burtt N P Guiducci C Gupta N Gao X Qi Y Yuki Y Piechocka-Trocha A Cutrell E Rosenberg R Moss K L Lemay P O'Leary J Schaefer T Verma P Toth I Block B Baker B Rothchild A Lian J Proudfoot J Alvino D M Vine S Addo M M Allen T M Altfeld M Henn M R Le Gall S Streeck H Haas D W Kuritzkes D R Robbins G K Shafer R W Gulick R M Shikuma C M Haubrich R Riddler S Sax P E Daar E S Ribaudo H J Agan B Agarwal S Ahern R L Allen B L Altidor S Altschuler E L Ambardar S Anastos K Anderson B Anderson V Andrady U Antoniskis D Bangsberg D Barbaro D Barrie W Bartczak J Barton S Basden P Basgoz N Bazner S Bellos N C Benson A M Berger J Bernard N F Bernard A M Birch C Bodner S J Bolan R K Boudreaux E T Bradley M Braun J F Brndjar J E Brown S J Brown K Brown S T Burack J Bush LM Cafaro V Campbell O Campbell J Carlson R H Carmichael J K Casey K K Cavacuiti C Celestin G Chambers S T Chez N Chirch L M Cimoch P J Cohen D Cohn LE Conway B Cooper D A Cornelson B Cox D T Cristofano M V Cuchural G Jr Czartoski J L Dahman J M Daly J S Davis B T Davis K Davod S M DeJesus E Dietz C A Dunham E Dunn M E Ellerin T B Eron J J Fangman J J Farel C E Ferlazzo H Fidler S Fleenor-Ford A Frankel R Freedberg K A French N K Fuchs JD Fuller J D Gaberman J Gallant J E Gandhi R T Garcia E Garmon D Gathe J C Jr Gaultier C R Gebre W Gilman F D Gilson I Goepfert P A Gottlieb M S Goulston C Groger R K Gurley T D Haber S Hardwicke R Hardy W D Harrigan P R Hawkins T N Heath S Hecht F M Henry W K Hladek M Hoffman R P Horton J M Hsu R K Huhn G D Hunt P Hupert M J Illeman M L Jaeger H Jellinger R M John M Johnson J A Johnson K L Johnson H Johnson K Joly J Jordan W C Kauffman C A Khanlou H Killian R K Kim A Y Kim D D Kinder C A Kirchner J T Kogelman L Kojic E M Korthuis P T Kurisu W Kwon D S LaMar M Lampiris H Lanzafame M Lederman M M Lee D M Lee J M Lee M J Lee E T Lemoine J Levy J A Llibre J M Liguori M A Little S J Liu A Y Lopez A J Loutfy M R Loy D Mohammed D Y Man A Mansour M K Marconi V C Markowitz M Marques R Martin J N Martin H L Jr Mayer K H McElrath M J McGhee T A McGovern B H McGowan K McIntyre D Mcleod GX Menezes P Mesa G Metroka CE Meyer-Olson D Miller A O Montgomery K Mounzer K C Nagami E H Nagin I Nahass R G Nelson M O Nielsen C Norene D L O'Connor D H Ojikutu B O Okulicz J Oladehin O O Oldfield E C Olender S A Ostrowski M Owen WF Jr Pae E Parsonnet J Pavlatos A M Perlmutter A M Pierce M N Pincus J M Pisani L Price L J Proia L Prokesch R C Pujet H C Ramgopal M Rathod A Rausch M Ravishankar J Rhame F S Richards C S Richman D D Rodes B Rodriguez M Rose R C 3rd Rosenberg E S Rosenthal D Ross P E Rubin D S Rumbaugh E Saenz L Salvaggio M R Sanchez WC Sanjana V M Santiago S Schmidt W Schuitemaker H Sestak P M Shalit P Shay W Shirvani V N Silebi V I Sizemore J M Jr Skolnik P R Sokol-Anderson M Sosman J M Stabile P Stapleton J T Starrett S Stein F Stellbrink H J Sterman FL Stone V E Stone D R Tambussi G Taplitz R A Tedaldi E M Telenti A Theisen W Torres R Tosiello L Tremblay C Tribble M A Trinh P D Tsao A Ueda P Vaccaro A Valadas E Vanig T J Vecino I Vega V M Veikley W Wade B H Walworth C Wanidworanun C Ward D J Warner D A Weber R D Webster D Weis S Wheeler D A White D J Wilkins E Winston A Wlodaver C G van't Wout A Wright D P Yang O O Yurdin D L Zabukovic B W Zachary K C Zeeman B Zhao M	2010	Science2010，330，6010：	1
3	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，2：	1
4	Prophylaxis against hepatitis B recurrencefollowing liver transplan-tation using conbination lamivudine and hepatitis B im-muneglobulin显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，585：	1
5	Prophylaxis against hepati- tis B recurrence following liver transplantation using combination lami- vudine and hepatitis B immune globulin 显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，2：	1
6	Quality of Life and Symptom Control after Stent Placement or Surgical Palliation of Malignant Colorectal Obstruction显示文摘	Satish Nagula Nicole Ishill Carla Nash Arnold J. Markowitz Mark A. Schattner Larissa Temple Martin R. Weiser Howard T. Thaler Ann Zauber Hans Gerdes	2010	Journal of the American College of Surgeons2010，，1：	1
7	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudi- ne and hepatitis B immune globulin 显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，：	1
8	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin显示文摘	MARKOWITZ J S MARTIN P CONRAD A J	1998	Hepatology1998，28，：	1
9	A SIMPLE MODEL TO ESTIMATE SURVIVAL AFTER RETRANSPLANTATION OF THE LIVER1显示文摘	James F. Markmann Jeffrey Gornbein Jay S. Markowitz Marlon F. Levy Goran B. Klintmalm Hasan Yersiz Marcia Morrisey Kenneth Drazan Douglas G. Farmer Rafik M. Ghobrial John Goss Phillip Seu Paul Martin Leonard I. Goldstein Ronald W. Busuttil	1999	Transplantation1999，，3：	1
10	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin显示文摘	Markowitz JS Martin P Conrad Al Markmann JF Seu P. Yersiz H. Goss JA. Schmidt P Pakrasi A Artinian L. Murray NG magawa DK Holt C Goldstein LI Stribling R BusuttiI RW		0，，：	1
11	Long-Term Survival After Retransplantation of the Liver显示文摘	James F. Markmann Jay S. Markowitz Hasan Yersiz Marcia Morrisey Douglas G. Farmer Dana A. Farmer John Goss Rafik Ghobrial Sue V. McDiarmid Rise Stribling Paul Martin Leonard I. Goldstein Phillip Seu Christopher Shackleton Ronald W. Busuttil	1997	Annals of Surgery1997，，4：	1
12	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，2：	1
13	Prophylaxis against hepati tis B recurrence following liver transplantation using combination lamivudine an d hepatitis B immune globulin显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，2：	1
14	Prophylaxis against hepatitis B recunence following liver transplantation using combination lamivudine and hepatitis B immune globuhn显示文摘	Markowitz JS Martin P Conrad A J		Hepatology0，，：	1
15	Prophylaxis against heptitis B recurrence following liver transpmation using combination lamivudine and heptitis B immune globulin显示文摘	Martin P Conrad A	1998	Heptology1998，28，：	1
16	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin显示文摘	Markowitz J Martin P Conrad A	1998	Hepatology1998，28，2：	1
17	A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease显示文摘	James Markowitz Kathy Grancher Nina Kohn Martin Lesser Fredric Daum	2000	Gastroenterology2000，，4：	1
18	Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin显示文摘	Martin P Conrad AJ	1998	Hepatology1998，28，：	1
19	Prophylaxis against hepatitis B recurrence following liver transplantation using combi- nation lamivudine and hepatitis B immune globulin 显示文摘	Markowitz JS Martin P Conrad AJ	1998	Hepatology1998，28，2：	1
20	POWER1和2试验中对曾治疗HIV-1感染患者给予地瑞那韦-利托那韦治疗48周时的疗效与安全性:2项随机试验资料的合并亚组分析显示文摘背景连续、随机、多国性POWER1和2ⅡB期研究旨在评价地瑞那韦(darunavir)联合应用小剂量利托那韦(ritonavir)对曾治疗HIV-1感染患者的疗效与安全性。本文作者进行了一项合并的亚组分析,对接受推荐剂量地瑞那韦-利托那韦的患者与接受其他蛋白酶抑制剂(PI)的患者进行比较,以提供治疗48周时有关疗效与安全性的最新信息。方法在24周的剂量探索期和主要疗效分析后,被随机分入地瑞那韦-利托那韦组的患者继续服药600/100mg2次/d.而对照PI组的患者继续按指定治疗方案进入较长期的开放标记期;所有患者继续接受最佳背景治疗。对在分析时已达到第48周或提前停药的患者进行了评估;地瑞那韦~利托那韦组只纳入了从基线开始就服用600/100mg2次/d的患者。采用意向性治疗分析。POWER2研究(TMC114-C202)在ClinicalTrials.gov注册(NCT00071097)。结果48周时,110例地瑞那韦-利托那韦组患者中有67例(61%)病毒载量较基线下降≥1 log10拷贝/ml,而120例对照PI组患者中仅有18例(15%)(主要终点;反应率差值46%,95%CI35%~57%,P〈0,0001)。根据logisticS/归模型,该模型将分层因素(基线时原发PI突变数、恩夫韦地的使用、基线病毒载量)和研究作为协变量,反应率差值为50%(OR 11.72,95%CI 5.75~23.89)。在地瑞那韦-利托那韦组,如果校正治疗暴露,则不良事件率大都低于或近似于对照组。没有发现意外的安全事件。结论采用地瑞那韦-利托那韦600/100mg 2次/d加最佳背景治疗的疗效反应大于对照PI。且疗效至少持续48周,尤其在曾治疗HIV患者中具有良好的安全性和耐受性。这一方案扩展了此类患者的治疗选择。	Bonaventura Claret Nicholas Bellos Jean-Michel Molina David Cooper Jean-Christophe Goffard Adriano Lazzarin Andrej Wohrmann Christine Katlama Timothy Wilkin Richard Haubrich Calvin Cohen Charles Farthing Dushyantha Jayaweera Martin Markowitz Peter Ruane Sabrina Spinosa-Guzman Eric Lefebvre 王介明(译) 李宏建(译)	2008	世界临床医学2008，2，2：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示